Ping An Biomedical Announces Planned Acquisition of Three Tumor Cell-Related Medical Technology Patents to Build a Core Oncology and Biotech Intellectual Property Portfolio
Ping An Biomedical Signs LOI To Acquire Three Oncology Technology Patents For $2M-$2.5M
Ping An Biomedical Announces 1-for-40 Reverse Stock Split
Ping An Biomedical Announces 1-For-40 Reverse Stock Split, Effective Oct. 23
Ping An Biomedical and Yuan Sheng Mei Yan Sign Strategic Cooperation Agreement, Targeting RMB 500 Million in Sales Over Three Years
Ping An Biomedical Signs Agreement With Yuan Sheng Mei Yan Health Services To Be Its Channel Development Service Provider; Plans To Achieve RMB500M Cumulative Sales Within Three Years
All Resolutions Passed at Ping An Biomedical AGM, Clearing Path for Restructured Share Capital
Ping An Biomedical Enters Investment Memorandum With Future Biotechnology For Up To $90M
Ping An Biomedical Co., Ltd Announces Strategic Investment in Future Biotechnology Group to Advance Collaborative Development of the Biopharmaceutical Industry
Ping An Biomedical Co., Ltd. Receives Strategic Investment from Leading Industry Capital, Accelerating Growth in Biopharmaceutical Innovation
Ping An Bio Announces Non-Binding $30M Cash Investment, $60M Acquisition Plan With Future Biotechnology
Ping An Biomedical Enters Share Purchase Agreements With Several Investors, 58 Group's Yao Jinbo, Amiba Capital's Wang Donghui, And Magcloud's Li Daxue
Ping An Biomedical Co., Ltd. Announces Receipt of Nasdaq Minimum Bid Price Deficiency Letter
Ping An Biomedical Receives Nasdaq Deficiency Letter For Failing To Meet $1 Minimum Bid Price, Granted Compliance Period Until May 25, 2026
Majestic Ideal Holdings Ltd Announces Approval of Name Change to "Ping An Biomedical Co., Ltd." at Extraordinary General Meeting
Majestic Ideal Holdings Limited Announced Closing of Initial Public Offering
Majestic Ideal Holdings Limited Announces Pricing of Initial Public Offering and Listing on Nasdaq
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.